Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Argent Biopharma ( (AU:RGT) ) just unveiled an announcement.
Argent Biopharma Limited has applied for quotation on the ASX of 1,250,000 new fully paid ordinary shares under the code RGT, with an issue date of March 20, 2026. The additional securities broaden the company’s free float and may enhance trading liquidity, modestly expanding its capital base and potentially supporting future operational or strategic initiatives.
The move confirms Argent Biopharma’s continued utilization of the equity capital markets as a funding and corporate tool. For shareholders and prospective investors, the new quotation provides a clearer view of the company’s evolving capital structure and may influence valuation and market positioning within the biopharma sector.
The most recent analyst rating on (AU:RGT) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
More about Argent Biopharma
Argent Biopharma Limited is a listed pharmaceutical company on the ASX under the ticker RGT. The company operates in the biopharmaceutical sector and is focused on developing and commercializing healthcare or drug-related products, targeting investors seeking exposure to the life sciences industry.
Average Trading Volume: 192,762
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.96M
For detailed information about RGT stock, go to TipRanks’ Stock Analysis page.